Actively Recruiting
Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation
Led by National Cancer Institute, Slovakia · Updated on 2025-05-29
100
Participants Needed
1
Research Sites
300 weeks
Total Duration
On this page
Sponsors
N
National Cancer Institute, Slovakia
Lead Sponsor
S
Slovak Academy of Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
Numerous in vitro and animal studies as well as growing number of clinical studies support the important role of microbiome in carcinogenesis and cancer treatment. Detection of changes in patients´ microbiome following hematopoietic cell transplantation/CAR-T cell therapy and correlations with adverse transplant outcomes, mainly infectious complications, acute and chronic GvHD, disease recurrence etc. could serve as predictive markers of immune recovery and treatment response.
CONDITIONS
Official Title
Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed written informed consent
- Aged 18 years or older
- Patients planned to be treated by high-dose chemotherapy and hematopoietic cell transplantation or by CAR-T cell therapy at National Cancer Institute, Slovakia
You will not qualify if you...
- Patients not matching inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Cancer Institute
Bratislava, Slovakia, Slovakia, 83310
Actively Recruiting
Research Team
B
Barbora Kašperová, MD
CONTACT
S
Sona Ciernikova, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here